S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00445601
Recruitment Status : Completed
First Posted : March 9, 2007
Last Update Posted : October 6, 2016
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Completed
  Primary Completion Date : September 2016
  Study Completion Date : September 2016

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 December 21, 2017 January 18, 2018
2 February 13, 2018 March 12, 2018
3 March 12, 2018